Evidence map›Paper›PMID 36558981›Full record

ArticlePharmaceuticals (Basel, Switzerland)2022

Optimized Therapeutic

Yitian Wu, Xiaojun Zhang, Xiaojiang Duan, Xing Yang, Feng Wang, Jinming Zhang

Open access · goldAbstract read
In one paragraph

Article in Pharmaceuticals (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
  3. Comparative efficacy of radical prostatectomy and radiotherapy in the treatment of high-risk prostate cancer.Technology and health care : official journal of the European Society for Engineering and Medicine · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Yitian WuDepartment of Nuclear Medicine, Chinese PLA General Hospital, Beijing 100853, China.ORCID 0000-0003-0517-1098
Xiaojun ZhangDepartment of Nuclear Medicine, Chinese PLA General Hospital, Beijing 100853, China.
Xiaojiang DuanDepartment of Nuclear Medicine, Peking University First Hospital, Beijing 100034, China.
Xing YangDepartment of Nuclear Medicine, Peking University First Hospital, Beijing 100034, China.ORCID 0000-0001-5186-4990
Feng WangDepartment of Nuclear Medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing 210006, China.
Jinming ZhangDepartment of Nuclear Medicine, Chinese PLA General Hospital, Beijing 100853, China.
Chinese PLA General Hospital · CNPeking University · CNNanjing Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Clinical trials have shown the significant efficacy of [

Indexed as

177Luprostate cancerPSMASPECTtherapeutic

Identifiers

PMID36558981
PMCPMC9782218
OpenAlexW4311968047

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.